Estimations des analystes de Wall Street pour PDS Biotechnology Corporation (PDSB): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Consensus des analystes
| Achat fort | 0 |
| Achat | 6 |
| Conserver | 1 |
| Vente | 0 |
| Vente forte | 0 |
| Analystes au total | 7 |
| Note moyenne (1-5) | 0.86 |
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.11 | ||
| 2026-08-13 | $-0.18 | $-0.13 | -38.5% |
| 2026-05-13 | $-0.13 | $-0.15 | +13.3% |
| 2026-03-30 | $-0.14 | $-0.20 | +30.0% |
| 2025-11-13 | $-0.19 | $-0.21 | +9.5% |
| 2025-08-13 | $-0.21 | $-0.24 | +12.5% |
| 2025-05-14 | $-0.21 | $-0.25 | +16.0% |
| 2025-03-27 | $-0.21 | $-0.29 | +27.6% |
Ratios de valorisation
| Prix / Valeur comptable | -9.10 |
| EV / EBITDA | -1.16 |
| Rendement du dividende | 0.00% |
Compte de Résultat (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coût des Ventes | $100117 | $182918 | $69118 | $98414 | 0 | 0 | 0 | $57326 | $59791 | 0 |
| Marge Brute | -$100000 | -$183000 | -$69118 | -$98414 | 0 | 0 | 0 | -$57326 | -$59791 | 0 |
| R&D | $24.8M | $34.3M | $830744 | $6.1M | $7.9M | $11.3M | $29.4M | $27.8M | $22.6M | $19.0M |
| Frais Généraux | $14.7M | $17.7M | $14.3M | $9.3M | $7.0M | $10.2M | $12.2M | $15.3M | $13.7M | $12.5M |
| Charges Opérationnelles | $39.5M | $52.0M | $3.6M | $15.4M | $14.9M | $21.4M | $41.7M | $43.0M | $36.3M | $31.5M |
| Résultat Opérationnel | -$39.5M | -$52.0M | -$43.1M | -$15.5M | -$14.9M | -$21.4M | -$41.7M | -$43.0M | -$36.3M | -$31.5M |
| EBITDA | -$39.4M | -$51.1M | -$3.6M | -$7.2M | -$14.9M | -$21.4M | -$40.7M | -$40.1M | -$33.7M | -$30.3M |
| Charges d'Intérêt | $1.2M | $2.2M | $1.4M | $33559 | 0 | 0 | $1.3M | $4.2M | $4.7M | $5.3M |
| Résultat Avant Impôts | -$40.7M | -$53.4M | -$3.8M | -$7.4M | -$14.8M | -$21.4M | -$42.1M | -$44.3M | -$38.5M | -$35.7M |
| Impôts | 0 | -$2.6M | -$2.8M | -$381513 | 0 | -$4.5M | -$1.2M | -$1.4M | -$869169 | -$1.2M |
| Résultat Net | -$38.8M | -$50.9M | -$40.9M | -$7.0M | -$14.8M | -$16.9M | -$40.9M | -$42.9M | -$37.6M | -$34.5M |
| BPA | $-26.90 | $-33.47 | $-26.16 | $-1.44 | $-0.89 | $-0.66 | $-1.43 | $-1.39 | $-1.03 | $-0.74 |
| BPA Dilué | $-26.90 | $-33.47 | $-10.25 | $-1.44 | $-0.89 | $-0.66 | $-1.43 | $-1.39 | $-1.03 | $-0.74 |
| Actions en Circulation (Diluées) | $1.4M | $1.5M | $4.0M | $4.9M | $16.7M | $25.6M | $28.6M | $31.0M | $36.5M | $46.4M |
Prix
| Prix | $0.99 |
| Capitalisation | $55M |
| Bourse | NASDAQ |
| Pays | US |
Entreprises liées: ANVS · ATNM · FGEN · INMB · KZR · LVTX · OKUR
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de PDSB: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions